Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase G Kukolj, GA McGibbon, G McKercher, M Marquis, S Lefebvre, ... Journal of Biological Chemistry 280 (47), 39260-39267, 2005 | 165 | 2005 |
Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells PL Beaulieu, Y Bousquet, J Gauthier, J Gillard, M Marquis, G McKercher, ... Journal of medicinal chemistry 47 (27), 6884-6892, 2004 | 123 | 2004 |
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA A Pause, G Kukolj, M Bailey, M Brault, F Dô, T Halmos, L Lagacé, ... Journal of Biological Chemistry 278 (22), 20374-20380, 2003 | 122 | 2003 |
A disulfide-bridged mutant of natriuretic peptide receptor-A displays constitutive activity: role of receptor dimerization in signal transduction J Labrecque, N Mc Nicoll, M Marquis, A De Léan Journal of Biological Chemistry 274 (14), 9752-9759, 1999 | 86 | 1999 |
Risk of delayed intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: systematic review and meta-analysis JM Chauny, M Marquis, F Bernard, D Williamson, M Albert, M Laroche, ... The Journal of emergency medicine 51 (5), 519-528, 2016 | 84 | 2016 |
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment A Erhardt, K Deterding, Y Benhamou, M Reiser, X Forns, S Pol, JL Calleja, ... Antiviral therapy 14 (1), 23-32, 2009 | 83 | 2009 |
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin D Larrey, AW Lohse, V De Ledinghen, C Trepo, T Gerlach, JP Zarski, ... Journal of hepatology 57 (1), 39-46, 2012 | 53 | 2012 |
In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335 L Lagacé, PW White, C Bousquet, N Dansereau, F Dô, M Llinas-Brunet, ... Antimicrobial agents and chemotherapy 56 (1), 569-572, 2012 | 53 | 2012 |
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir KL Berger, I Triki, M Cartier, M Marquis, MJ Massariol, WO Böcher, ... Antimicrobial agents and chemotherapy 58 (2), 698-705, 2014 | 42 | 2014 |
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency O Hucke, R Coulombe, P Bonneau, M Bertrand-Laperle, C Brochu, ... Journal of medicinal chemistry 57 (5), 1932-1943, 2014 | 37 | 2014 |
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in … D Larrey, AW Lohse, C Trepo, JP Bronowicki, K Arastéh, M Bourlière, ... Antimicrobial agents and chemotherapy 57 (10), 4727-4735, 2013 | 29 | 2013 |
Prognostic impact of the conversion to a shockable rhythm from a non-shockable rhythm for patients suffering from out-of-hospital cardiac arrest A Cournoyer, S Cossette, BJ Potter, R Daoust, L de Montigny, ... Resuscitation 140, 43-49, 2019 | 28 | 2019 |
Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3–NS4A proteins MJ Massariol, S Zhao, M Marquis, D Thibeault, PW White Biochemical and biophysical research communications 391 (1), 692-697, 2010 | 28 | 2010 |
Inhibitor-resistant HCV NS3 protease G Kukolj, L Lagacé, M Marquis, D Lamarre, A Pause US Patent 7,208,309, 2007 | 27 | 2007 |
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study KL Berger, L Lagacé, I Triki, M Cartier, M Marquis, C Lawetz, R Bethell, ... Antimicrobial agents and chemotherapy 57 (10), 4928-4936, 2013 | 23 | 2013 |
Genotypic and Phenotypic Analysis of the NS5B Polymerase Region from Viral Isolates of HCV Chronically Infected Patients Treated with BI 207127 for 5 Days' Monotherapy L Lagace, M Cartier, G Laflamme, C Lawetz, M Marquis, I Triki, ... Hepatology 52 (4), 1205A-1206A, 2010 | 22 | 2010 |
Evaluating acute pain intensity relief: challenges when using an 11-point numerical rating scale JM Chauny, J Paquet, G Lavigne, M Marquis, R Daoust Pain 157 (2), 355-360, 2016 | 20 | 2016 |
Evaluation of interventions to reduce opioid prescribing for patients discharged from the emergency department: a systematic review and meta-analysis R Daoust, J Paquet, M Marquis, JM Chauny, D Williamson, V Huard, ... JAMA network open 5 (1), e2143425-e2143425, 2022 | 18 | 2022 |
Oxygen therapy and risk of infection for health care workers caring for patients with viral severe acute respiratory infection: a systematic review and meta-analysis A Cournoyer, S Grand’Maison, AM Lonergan, J Lessard, JM Chauny, ... Annals of Emergency Medicine 77 (1), 19-31, 2021 | 13 | 2021 |
822 PRECLINICAL CHARACTERIZATION OF THE HEPATITIS C VIRUS NS5B POLYMERASE NON-NUCLEOSIDE INHIBITOR BI 207127 PL Beaulieu, PC Anderson, C Brochu, M Bos, M Cordingley, J Duan, ... Journal of Hepatology, S321, 2012 | 13 | 2012 |